The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus.
Teodor SalmenFlorin-Teodor BobircaIoana-Cristina BicaDoina-Andrada MihaiCorina PopAnca Mihaela Pantea StoianPublished in: Life (Basel, Switzerland) (2023)
In this retrospective analysis, both SGLT-2is and GLP-1 RAs, when used in conjunction with other glucose-lowering, blood-pressure-lowering, and lipid-lowering medications, appeared to be safe for the management of T2DM.